DRAMMATIC

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)

What's the purpose of the trial?

Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20.

Trial status

Active, Not Recruiting

Phase
Phase 3
Enrollment
1100
Last Updated
1 month ago
Patient Screener

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.